Company news
Sinotherapeutics, Inc. news in 2026
Sinotherapeutics, Inc.'s news releases, calls and decks from 2026, newest first.
(688247)"SINOTHERAPEUTICS INC."Report for Q3 2026
October 28, 2026
(688247)"SINOTHERAPEUTICS INC."Announcement on Attending the Q3 2026 Collective Performance Briefing of Listed Companies in Shanghai Jurisdiction
October 28, 2026
(688247)"SINOTHERAPEUTICS INC."Announcement on Release of Pledge of Certain Shares Held by Shareholder
October 19, 2026
(688247)"SINOTHERAPEUTICS INC."Announcement on Implementation of Dividend Distribution for the First Half of 2026
October 16, 2026
(688247)"SINOTHERAPEUTICS INC."Announcement on Completion of Transfer of Certain Shares under Gratuitous Donation by Shareholder
October 15, 2026
Announcement on Change of Signing Certified Public Accountant
September 10, 2026
Special Report on the Deposit, Management and Actual Use of Raised Funds for the First Half of 2026
August 27, 2026
Announcement on Using Certain Idle Raised Funds for Cash Management
August 4, 2026
Announcement on Voluntary Disclosure of Proposed Selection in the National Centralized Drug Procurement
August 3, 2026
Announcement on Voluntary Disclosure of Approval of Posaconazole Enteric-coated Tablets via the EU Decentralised Procedure (DCP)
July 24, 2026
Announcement on Voluntary Disclosure of Doxofylline Tablets Passing the Consistency Evaluation of Generic Drugs and the Addition of a New Specification
July 13, 2026
Announcement on Abnormal Fluctuations in Stock Trading
July 2, 2026
Announcement on Implementation of Dividend Distribution for 2025
June 21, 2026
Announcement on the Expiry of Planned Time for Shareholders with Over 5% Shares to Reduce Shares and Results of Shareholding Reduction
June 10, 2026
Senior Management Member" -- Announcement on Completing Term Change and Election of the Board of Directors and Appointing Senior Management Members and Securities Affairs Representative, as well as Departure of Core Technical Personnel
May 28, 2026
Announcement on Voluntary Disclosure of Obtaining the Colombian INVIMA Approval for Bupropion Hydrochloride Extended-release Tablets
May 25, 2026
Notice on Convening the 2025 Annual General Meeting
April 29, 2026
Science and Technology for People's Well-being - Achievement of Enterprises on SSE STAR Market and Its Empowerment of People's Livelihood Conference
April 28, 2026
Indicative Announcement on Equity Change of Shareholder with Over 5% Shares Reaching an Integral Multiple of 1% and 5% Scale
April 14, 2026
Announcement on Resolutions of the 25th Meeting of the 2nd Board of Directors
April 1, 2026
Publicity Explanation and Verification Opinions of the Remuneration and Appraisal Committee of the Board of Directors on List of Initially Granted Incentive Objects in the 2025 Restricted Stock Incentive Plan
March 26, 2026
Announcement on Voluntary Disclosure of Sinotherapeutics® Tomato Red Grape Seed Extract Tablets Obtaining the Domestic Health Food Registration Certificate
March 17, 2026
Notice on Convening the 1st Extraordinary General Meeting in 2026
March 16, 2026
Announcement on Voluntary Disclosure of Clinical Trial Applications for Collaborative Product Enzalutamide Tablets Approved by China NMPA
March 13, 2026
Announcement on Approval by Shanghai Municipal State-owned Assets Supervision and Administration Commission for Abstract of 2025 Restricted Stock Incentive Plan (Revised Draft)
March 10, 2026
Announcement on Voluntary Disclosure of Obtaining US FDA Approval Number for the Company’s Vitamin K1 Tablets
March 2, 2026
Announcement on Preliminary Earnings Estimate for 2025
February 27, 2026
Announcement on Voluntary Disclosure of the Proposed Selection of Products in the National Continuation Drug Procurement
February 10, 2026
Announcement on Shareholding Reduction Plan for Shareholders with Over 5% Shares
February 9, 2026
Announcement on Provision for Asset Impairment for 2025
January 29, 2026
Summary Announcement on 2025 Restricted Stock Incentive Plan (Revised Draft)
January 14, 2026
Announcement on Voluntary Disclosure of Clinical Trial Applications for Eisaiconazole Sulfate for Injection Approved by China NMPA
January 6, 2026